Renal Cell Cancer Tumor Markers
- Determine the expression levels of novel genes and proteins (HFARP, HAMGR28, HE9NG77)
in frozen normal tissue and tumor tissue samples from patients who have undergone
nephrectomy for renal cell cancer.
- Correlate gene and protein expression levels with disease stage, tumor size, and
pathology reports (e.g., cell type, grade, and tissue architecture) in order to
evaluate the rate of gene and protein expression as targets for future therapeutic
- Compare proteomic screening of potential biomarkers using existing plasma and/or urine
samples from patients with renal cell cancer or breast cancer stored in the CCCWFU
Tumor Tissue Core with tissue samples from patients enrolled in this study.
OUTLINE: Normal and tumor tissue collected from patients who have undergone nephrectomy and
diagnostic and therapeutic intervention for renal cell cancer is analyzed for
histopathological expression and compared to normal kidney cells by northern blot. Tissue
samples are evaluated by RNA and protein extraction and analyzed by gel electrophoresis,
blotting, and phosphor-imaging for induction or suppression of genes and protein levels.
These data are correlated with clinical stage, tumor size, and histopathological grade and
architecture of the patient's disease.
Time Perspective: Prospective
Expression levels of novel genes and proteins (HFARP, HAMGR28, HE9NG77) in frozen normal tissue and tumor tissue
Frank M. Torti, MD, MPH
Comprehensive Cancer Center of Wake Forest University
United States: Institutional Review Board
|Wake Forest University Comprehensive Cancer Center||Winston-Salem, North Carolina 27157-1096|